Establishment Labs Holdings Inc. has formally submitted its Motiva SmoothSilk® Round and Ergonomix® breast implants for U.S. FDA approval in primary and revision breast reconstruction. The company previously secured FDA clearance for these devices in elective augmentation on September 27, 2024. By targeting the reconstruction segment—where innovation has been limited for over a decade—Establishment Labs aims to address a clinically necessary market estimated at over 100,000 annual mastectomy procedures in the United States. Management expects the reconstruction indication to drive incremental revenue growth, leveraging existing manufacturing capacity in Costa Rica compliant with ISO 13485:2016 and FDA 21 CFR 820 standards.

The submission is backed by a U.S. IDE study conducted across 17 American centers and one Western European site, enrolling 274 post-mastectomy patients (220 primary reconstructions and 54 revisions). Investigators reported that the patented SmoothSilk® surface demonstrated low inflammation rates below 2% at 12 months, while the Ergonomix® implant’s adaptive shape technology showed a patient satisfaction score exceeding 90% on BREAST-Q assessments. Since market launch in augmentation, more than 60,000 Motiva devices have been sold in the U.S., underscoring rapid adoption by plastic surgeons.

Despite the strategic FDA filing, ESTA shares declined approximately 6% on the day of the announcement, on trading volume nearly double the 30-day average. Investors cited concerns over timing of reconstruction approval and the anticipated six- to nine-month review process. However, analysts note the company’s broader portfolio—including the FDA-cleared Motiva Flora® tissue expander in over 200 cancer centers and more than four million Motiva implants delivered globally since 2010—provides multiple growth levers. Establishment Labs holds over 200 patent applications and reports distribution in more than 90 countries, positioning it for sustained market penetration once reconstruction clearance is obtained.